Renalytix AI (GB:RENX) has released an update.
Renalytix AI, an AI-enabled in vitro diagnostics firm specializing in kidney disease management, has announced a change in its brokerage arrangements. Investec Bank plc will no longer serve as Joint Broker, effective August 31, 2024, with Oberon Capital now sharing the role alongside Stifel, which remains the company’s Nominated Adviser.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
